NCT00299507

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

Conditions

• Macular Degeneration

Interventions

Type	Name	Description
DRUG	Anecortave Acetate Sterile Suspension, 30 mg/mL	One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
DRUG	Anecortave Acetate Sterile Suspension, 60 mg/mL	One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
OTHER	Anecortave Acetate Vehicle	One 0.5 mL sham injection at 6 month intervals

Timeline

• Start date: 2005-03-01
• Primary completion: 2008-04-01
• Completion: 2008-04-01
• First posted: 2006-03-07
• Last updated: 2012-11-28

Locations

1 site across 1 country: United States